Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
12
12 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- OlverembatinibPhase 34 trials
Ascentage Pharma Group Inc. · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- single CNCT19Phase 23 trials
Juventas Cell Therapy Ltd. · Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- CRC01Phase 22 trials
Curocell Inc. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
- rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- YK012Phase 22 trials
Excyte Biopharma Ltd · Systemic Lupus Erythematosus (SLE), B-cell Acute Lymphoblastic Leukemia
- TBI-1501Phase 21 trial
Takara Bio Inc. · Lymphoblastic Leukemia, Acute Adult
- TGRX-814Phase 21 trial
Shenzhen TargetRx Co., Ltd. · Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia
- UCART22Phase 21 trial
Cellectis S.A. · B-cell Acute Lymphoblastic Leukemia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.